Citable company snapshot
Charles River Laboratories's latest SEC-sourced 2026-06-27 period shows $1.00B in revenue and $-1.48M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 27, 2026 | $1.00B | $995.83M | +0.8% |
| Gross Profit | Dec 26, 2020 | $299.97M | $289.27M | +3.7% |
| Operating Income | Jun 27, 2026 | $119.89M | $119.90M | -0.0% |
| Net Income | Jun 27, 2026 | $-1.48M | $-14.84M | +90.0% |
| Operating Cash Flow (computed) | Jun 27, 2026 | $179.72M | $41.08M | +337.5% |
| Free Cash Flow (computed) | Jun 27, 2026 | $148.62M | $-14.83M | +1102.1% |
Source: SEC EDGAR financial statements; period Jun 27, 2026; filed Aug 5, 2026; accession 0001100682-26-000118.
CRL company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.